Top 5 Things to Know About Janus Kinase Inhibitors

Sponsored by Elanco

Since the first JAK inhibitor was approved more than a decade ago for treating allergic and atopic dermatitis, our understanding of these medications has grown significantly. Register below to explore what we’ve learned and discover the latest addition to this drug class: ilunocitinib.